Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Passes Above 200-Day Moving Average – Should You Sell?

Posted by Brian Himes on Aug 13th, 2026

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX – Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $4.87 and traded as high as $8.15. Cumberland Pharmaceuticals shares last traded at $7.96, with a volume of 79,334 shares.

Wall Street Analysts Forecast Growth

CPIX has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Wednesday, June 24th. Wall Street Zen cut Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Check Out Our Latest Report on CPIX

Cumberland Pharmaceuticals Stock Down 0.1%

The company has a quick ratio of 0.79, a current ratio of 0.95 and a debt-to-equity ratio of 0.25. The firm has a market cap of $118.37 million, a PE ratio of -11.13 and a beta of 0.08. The firm’s 50 day moving average is $6.59 and its 200-day moving average is $4.90.

Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) last announced its earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.07). The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $8.50 million. Cumberland Pharmaceuticals had a negative return on equity of 26.77% and a negative net margin of 34.40%.

Cumberland Pharmaceuticals Dividend Announcement

The firm also recently disclosed a dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, July 23rd were issued a dividend of $1.50 per share.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd purchased a new position in Cumberland Pharmaceuticals during the second quarter worth about $34,000. Bridgeway Capital Management LLC grew its holdings in Cumberland Pharmaceuticals by 2.3% in the 2nd quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock valued at $631,000 after buying an additional 4,200 shares during the period. Dimensional Fund Advisors LP grew its holdings in Cumberland Pharmaceuticals by 11.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock valued at $876,000 after buying an additional 27,980 shares during the period. Two Sigma Investments LP increased its stake in shares of Cumberland Pharmaceuticals by 16.5% during the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after acquiring an additional 5,326 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Cumberland Pharmaceuticals by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock valued at $427,000 after acquiring an additional 5,653 shares during the last quarter. 15.51% of the stock is currently owned by institutional investors and hedge funds.

About Cumberland Pharmaceuticals

(Get Free Report)

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.